Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
11.04.2026 12:58
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Sm
Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use
09.04.2026 02:14
Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA, significantly widening the eligible treatment population in the U.S. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer patch in the share price, with a 30 day share price return of a 3.68% decline and a 1 year total shareholder return of a 7.96% decline. However, the 3 year and 5 year total...
Halozyme and Vertex sign deal for Hypercon technology
08.04.2026 09:32
Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup
03.04.2026 11:01
Vertex Pharmaceuticals (VRTX) combines strong growth fundamentals with a promising technical setup, offering a potential breakout opportunity for investors.
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
02.04.2026 18:08
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have outperformed the market lately as the 1.1% drawdown for healthcare stocks over the past six months was relatively better than the S&P 500’s 2.8% decline.
Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand
02.04.2026 14:13
Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. Read the latest analysis on the stock here.
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
01.04.2026 11:30
BOSTON, April 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA
The FDA Approves Expanded Use Of Vertex Pharmaceuticals' ALYFTREK (vanzacaftor/tezacaftor/ivacaftor) For Cystic Fibrosis In Patients 6 And Older
01.04.2026 07:35
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people
Jim Cramer on Corteva, Inc.: “I Would Continue to Own the Stock”
27.03.2026 18:01
Jim Cramer reviewed Corteva, Inc. (NYSE:CTVA) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Toward the end of the lightning round, a caller asked for Cramer’s thoughts on the stock, and he said: Okay, it’s an ag stock. We all know that crop protection and seeds are going […]
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
27.03.2026 15:09
I believe the market overreacted to Maze Therapeutics (MAZE) after strong Phase 2 HORIZON data for MZE829 in APOL1 kidney disease. Read the latest analysis on the stock here.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
24.03.2026 13:00
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
24.03.2026 11:27
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high profit margin stocks to buy. On March 10, Truist Securities boosted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $525 from $490, while keeping a Buy rating on the company’s shares. The firm cited encouraging Week-36 interim findings from Vertex’s Phase 3 RAINIER study in […]
How The Vertex Pharmaceuticals (VRTX) Story Is Shifting Toward Nephrology And Beyond Cystic Fibrosis
23.03.2026 05:03
Vertex Pharmaceuticals now carries a fair value estimate of US$547.72, compared with the prior US$504.04, as analysts refresh their assumptions around the stock. Much of that shift is being tied to a stronger narrative around the company’s nephrology platform, recent povetacicept data in IgA nephropathy, and a cluster of price target lifts and rating upgrades. In the following sections, you will see how this evolving analyst story could matter for how you track Vertex and respond to future...
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
21.03.2026 17:55
Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 /New to The Street, one of the longest-running U.S. and international sponsored ...
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
20.03.2026 11:58
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Positive RAINIER Trial Update And Accelerated IgAN Filing
20.03.2026 01:06
Why the RAINIER trial update matters for Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting positive interim Phase 3 RAINIER results for povetacicept in IgA nephropathy, including clinically meaningful proteinuria reductions and a safety profile that supported continued development. Alongside the data, the company is moving quickly with a rolling Biologics License Application and using a priority review voucher. These steps point to a...
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks
18.03.2026 13:28
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.
1 Momentum Stock to Research Further and 2 We Ignore
16.03.2026 13:55
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Vertex Data Sharpen Focus On Kidney And Pain Revenue Mix
15.03.2026 00:16
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting primary and secondary endpoints with strong efficacy and safety. The company is preparing a Biologics License Application for povetacicept, seeking accelerated FDA review using a priority review voucher. New Phase 4 results for JOURNAVX, suzetrigine, showed support for opioid free recovery across a range of surgical procedures. Vertex is advancing povetacicept into...
2 Reasons to Watch VRTX and 1 to Stay Cautious
13.03.2026 13:56
Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This performance may have investors wondering how to approach the situation.